Tris blocks Actavis’ ADHD generic
10-12-2020
EC fines Teva €60.5m over pay-for-delay deal
27-11-2020
‘Considerable increase’ in pay-for-delay settlements: FTC report
24-05-2019
Paul Brady Photography / Shutterstock.com
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission (FTC).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Federal Trade Commission, patent settlements, pay-for-delay, Actavis, anticompetition, generic competition, compensation
